Sutimlimab-jome (Enjaymo) for the Management of Hemolysis in Cold Agglutinin Disease (CAD)

Download PQI pdf

Last Updated: April 1, 2026

By: Cancer Care Associates of York | Piedmont Cancer Institute

About this PQI in Action

This PQI in Action is a follow-up to the Sutimlimab-jome (Enjaymo) for the Management of Hemolysis in Cold Agglutinin Disease (CAD) PQI and explores how the medically integrated teams collaborate and utilize the information found in the PQI as part of their daily practice.

Frequently Searched

Supported by

Sutimlimab-jome (Enjaymo) for the Management of Hemolysis in Cold Agglutinin Disease (CAD)

About this PQI in Action

More About This PQI in Action